<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03740204</url>
  </required_header>
  <id_info>
    <org_study_id>1R01MH116205</org_study_id>
    <nct_id>NCT03740204</nct_id>
  </id_info>
  <brief_title>The Role of Estrogen in the Neurobiology of Eating Disorders</brief_title>
  <official_title>The Role of Estrogen in the Neurobiology of Eating Disorders: A Study of Cognitive Flexibility and Reward in Eating Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double blind, placebo-controlled study of the effects of transdermal
      estradiol versus placebo on cognitive flexibility, reward processing, and eating disorder
      pathology in hypoestrogenemic female adolescents and young adults (ages 14-30) with an eating
      disorder characterized by extreme dietary restriction and/or excessive exercise. Subjects
      will be randomized 1:1 to 12 weeks of transdermal estradiol with cyclic progesterone or
      placebo patches and cyclic placebo pills. Study visits include a screening visit to determine
      eligibility and visits at baseline, 8 weeks, and 12 weeks. Study procedures comprise
      behavioral, neuroimaging, and endocrine assessments.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 13, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in inhibition-switching performance on the Delis-Kaplan Executive Function System Color-Word Interference Test (D-KEFS CWIT) with 17-β estradiol versus placebo</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Temporal Experience of Pleasure Scale (TEPS) Consummatory Pleasure score (Range: 8-48; direction: Higher values indicate more pronounced consummatory pleasure/better outcome) with 17-β estradiol versus placebo</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in delay discounting parameter k using the Monetary Choice Questionnaire with 17-β estradiol versus placebo</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Eating Disorder Inventory-2 (EDI-2) Body Dissatisfaction score (Range: 0-36; direction: Higher values indicate more pronounced body dissatisfaction/worse outcome) with 17-β estradiol versus placebo</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in EDI-2 Drive for Thinness score (Range: 0-28; direction: Higher values indicate more pronounced drive for thinness/worse outcome) with 17-β estradiol versus placebo</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in functional magnetic resonance imaging (fMRI) activation of the dorsolateral prefrontal cortex (DLPFC) and anterior cingulate cortex (ACC) during a task switching paradigm with 17-β estradiol versus placebo</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fMRI activation of the ventromedial prefrontal cortex (VMPFC) and ventral striatum in response to reward receipt with 17-β estradiol versus placebo</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fMRI activation of the VMPFC and ventral striatum during delay discounting with 17-β estradiol versus placebo</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Eating Disorder Examination (EDE) Dietary Restraint subscale (Range: 0-6; direction: Higher values indicate more pronounced dietary restraint/worse outcome) with 17-β estradiol versus placebo</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in caloric intake by 4-day food diary with 17-β estradiol versus placebo</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Eating Disorders</condition>
  <condition>Hypoestrogenemia</condition>
  <arm_group>
    <arm_group_label>17-β estradiol with cyclic progesterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>17-β estradiol transdermal patches with cyclic progesterone</intervention_name>
    <description>17-β estradiol transdermal patches (100 mcg 17-β estradiol/day) with cyclic progesterone (200 mg micronized progesterone daily for 12 days every month)</description>
    <arm_group_label>17-β estradiol with cyclic progesterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo patch and pill</intervention_name>
    <description>Placebo patch and pill</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Female

          -  14-30 years

          -  Clinically significant eating disorder characterized by restriction and/or excessive
             exercise and high drive for thinness

          -  Hypoestrogenemia: Oligo-amenorrhea defined as lack of menses for ≥3 months within a
             6-month period of oligomenorrhea (cycle length ≥5 weeks) or absence of menses at &gt;15
             years if premenarchal

          -  Low or normal weight defined by a weight that is &lt;85th percentile for 14-18 year olds
             and a body mass index &lt;25 kg/m2 for adults

        Exclusion criteria:

          -  Suicidal ideation where outpatient treatment is determined unsafe by study clinician

          -  DSM-5 eating disorders characterized by bingeing occurring on an average of ≥3x/month
             over the past 3 months

          -  Other causes of oligo-amenorrhea

          -  Medications that contain estrogen ± progesterone within the past 3 months

          -  Levonorgestrel-releasing intrauterine device if subject is unable to provide two to
             three weekly blood samples for estradiol of if estradiol levels are determined to be
             too high by study doctor

          -  Peanut allergy

          -  Neurological or psychiatric disorders that may impact neural circuitry of interest

          -  Lifetime history of seizure disorder or electroconvulsive therapy

          -  Pregnancy/breastfeeding

          -  Contraindications to MRI

          -  Gastrointestinal tract surgery

          -  Contraindications to estrogen use

          -  Any other significant illness or condition that the investigator determines could
             interfere with study participation or safety or put the subject at any unnecessary
             risk
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Madhusmita Misra, M.D., M.P.H.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Madhusmita Misra, M.D., M.P.H.</last_name>
    <phone>617-726-5790</phone>
    <email>mmisra@mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Franziska Plessow, Ph.D.</last_name>
    <phone>617-726-0784</phone>
    <email>fplessow@mgh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madhusmita Misra, M.D., M.P.H.</last_name>
      <phone>617-726-5790</phone>
      <email>mmisra@mgh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Franziska Plessow, Ph.D.</last_name>
      <phone>617-726-0784</phone>
      <email>fplessow@mgh.harvard.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>November 5, 2018</study_first_submitted>
  <study_first_submitted_qc>November 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2018</study_first_posted>
  <last_update_submitted>May 29, 2020</last_update_submitted>
  <last_update_submitted_qc>May 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Madhusmita Misra</investigator_full_name>
    <investigator_title>Division Chief, Pediatric Endocrinology</investigator_title>
  </responsible_party>
  <keyword>Adolescent</keyword>
  <keyword>Amenorrhea</keyword>
  <keyword>Anorexia Nervosa</keyword>
  <keyword>Cognitive Flexibility</keyword>
  <keyword>Dietary Restriction</keyword>
  <keyword>Eating Disorders</keyword>
  <keyword>Estrogen</keyword>
  <keyword>Excessive Exercise</keyword>
  <keyword>Females</keyword>
  <keyword>Hypoestrogenemia</keyword>
  <keyword>Reward</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Feeding and Eating Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

